Watch for ALX2004 Phase 1 data release in December 2026 and the KOL webinar; positive safety/efficacy could be a catalyst. Also monitor ASPEN-09-Breast enrollment updates and any changes to cash runway guidance.
Drugs in focus
ALXO drug pipeline →ALX2004
● Neutral Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- At least 5-7 years if successful (currently in Phase 1 dose-escalation; typical ADC development timelines from Phase 1 to approval span 5-8 years)
- Next catalyst
- None dated
What to watchInvestors should watch for the Phase 1 safety data readout in 2H 2026, which will be the first clinical data for this program. Positive results could unlock a $10M contingent tranche from HSVC's $50M credit facility. The data will also validate ALXO's internal ADC platform and inform whether the drug can differentiate in a competitive EGFR-targeted ADC landscape where MRG003 (becotatug vedotin) was already approved in China in November 2025.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 16 $1.00entry
- T+1 · 5d ago +0.50%α +1.51% · $1.01
- T+4 · todayOpen
- T+5 · in 24h Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ALX Oncology reported Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13, a miss. Cash runway extended to first half 2028. Key catalysts: ALX2004 Phase 1 safety/efficacy data expected December 2026, and ASPEN-09-Breast topline data from 120 patients expected in 2H 2027.
Key Financial Metrics
Key Facts
- Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13 (miss).
- Cash, cash equivalents and investments of $147.2M, sufficient to fund operations through first half of 2028.
- R&D expenses of $17.5M, essentially flat YoY.
- ALX2004 Phase 1 dose-escalation safety and early efficacy data expected December 2026.
- ASPEN-09-Breast topline data from 120 patients expected in second half of 2027.
- Non-GAAP net loss of $18.9M for Q3 2026 vs $19.6M in Q3 2025.
Financial Impact
Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13; cash burn rate of ~$7.6M per month.
Risk Factors
- EPS miss vs consensus indicates higher-than-expected operating losses.
- Clinical-stage biotech with no approved products; pipeline risk for both evorpacept and ALX2004.
- Cash runway only through first half of 2028; potential need for future capital raises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3403470 |
Track record
17 reports on ALXO
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +25.96% at T+20 after the May 8, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 19, 20262d ago SC 13G Neutral 4/10 Entry $0.9714 Now $1.06 +9.12% settles Nov 30
- Nov 16, 20265d ago Press Release Bearish 5/10 Viewing Entry $1.00 Now $1.06 −6.00% settles Nov 23
- Oct 16, 20265w ago SC 13D/A Neutral 4/10 Entry $1.14 to $1.13 Now $1.06 −7.02% ▼ −0.88% −0.73% vs SPY
- Oct 15, 20265w ago 8-K Mixed 6/10 Entry $1.06 to $1.17 Now $1.06 −0.00% ▲ +10.38% +10.81% vs SPY
- Sep 28, 20267w ago Press Release Mixed 5/10 Entry $1.39 to $1.21 Now $1.06 −23.74% ▼ −12.95% −14.15% vs SPY
- Aug 15, 202614w ago Institutional Cluster Neutral 4/10 Entry $1.97 to $1.99 Now $1.06 −46.19% ▲ +1.02% +2.21% vs SPY
- Aug 6, 202615w ago 8-K Neutral 4/10 Entry $2.11 to $1.94 Now $1.06 −49.76% ▼ −8.06% −9.27% vs SPY
- Jun 30, 202620w ago 8-K Neutral 3/10 Entry $2.06 to $2.36 Now $1.06 −48.54% ▲ +14.56% +14.30% vs SPY
- Jun 26, 202621w ago 8-K Neutral 5/10 Entry $2.20 to $2.19 Now $1.06 −51.82% ▼ −0.45% −1.84% vs SPY
- Jun 12, 202623w ago Institutional Cluster Bearish 5/10 Entry $1.58 to $1.53 Now $1.06 +32.91% ▲ +3.16% +3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers